sTMS Combined With CIMT and taVNS In Infants With Hemiplegia
Launched by MEDICAL UNIVERSITY OF SOUTH CAROLINA · Jul 3, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is exploring a new way to help infants who have weakness on one side of their body, often caused by brain injury around the time of birth. This condition, called hemiplegia, can lead to delays in movement and may be an early sign of cerebral palsy. The trial is testing whether a gentle electrical stimulation called transcutaneous vagus nerve stimulation (taVNS), combined with a special therapy that encourages use of the weaker arm (called constraint-induced movement therapy or CIMT), can improve arm and hand movement in infants aged 8 to 24 months.
Families interested in this study should have a child with noticeable weakness on one side and be able to commit to several appointments over two weeks, plus a follow-up after three months. During the study, researchers will also use a quick brain test to see if a single pulse of brain stimulation can cause movement, which helps identify which babies might benefit most from the treatment. Parents will be asked to complete questionnaires and share their observations about how well the therapy is working and how comfortable their child feels during the process. This trial is not yet enrolling participants but aims to find better ways to support infants with early movement challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants 8-24mo with hemiplegia or asymmetric weakness of one arm, with or without truncal and transitional motor delays
- • Gross Motor function Classification system (GMFCS) I - IV
- • Parents are able to make consecutive appointments for assessments and intervention over 2wks and complete the 3mo follow-up.
- • Parents are willing to fill out developmental questionnaires and provide the study team feedback on tolerability and outcomes.
- Exclusion Criteria:
- • previous CIMT within 3 months
- • GMFCS V or severe motor impairment/quadriplegia
- • uncorrected blindness/deafness, cardiomyopathy
- • poorly controlled seizure disorder
About Medical University Of South Carolina
The Medical University of South Carolina (MUSC) is a leading academic health center dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on translational medicine, MUSC leverages its extensive resources and expertise to facilitate groundbreaking studies across various medical disciplines. The institution is committed to fostering collaboration among researchers, healthcare professionals, and patients, ensuring that cutting-edge discoveries translate into effective treatments. As a pioneer in health education and research, MUSC plays a vital role in shaping the future of medicine and enhancing health outcomes in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charleston, South Carolina, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported